Evaluation of whole sporozoite vaccines for...

In the News

August CED message is here

Setting smart annual operational objectives The latest monthly message from IHI Chief Executive Director, Dr. Honorati Masanja, is here. This month the director underlines the setting of smart annual operational …

Vacancy: IHI recruits Project Manager for malaria vaccine trials

Vacancy: IHI recruits Project Manager for malaria vaccine trial project in Bagamoyo A clinical trials facility at Kingani in Bagamoyo. Ifakara Health Institute invites applications from suitably qualified candidates to …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …

Evaluation of whole sporozoite vaccines for malaria elimination

This program of work is led by a clinical team at the Ifakara Health Institute Clinical Trial Facility at Kingani, Bagamoyo (IHI – CTF) which is conducting a series of studies to evaluate the potential impact of whole sporozoite malaria vaccine candidates to prevent malaria infection and thereby block transmission with the goal of achieving malaria elimination in Sub-Sahara Africa. The work is conducted in two countries; Tanzania and Equatorial Guinea. Studies and major contributions of the work to date include:

dr-omar-in-the-labBSPZC1 (NCT01540903): The first Controlled Human Malaria Infection (CHMI) study using purified fully infectious malaria sporozoites in an African country was conducted at IHI-CTF at Kingani, Bagamoyo in 2012. This trial demonstrated the safety and infectivity of the fully infectious purified sporozoites (PfSPZ Challenge) leading to the establishment of the CHMI model for testing new malaria vaccines and drugs in Africa

BSPZV1 (NCT02132299): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2014-2015. This was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial to be conducted in Africa. The trial established a very good safety and tolerability profile for the PfSPZ vaccine and was the basis for further studies in Mali and Equatorial Guinea.

BSPZV2 (NCT02613520): Study conducted in IHI-CTF at Kingani, Bagamoyo between 2015- 2016. Worldwide, this was the first PfSPZ Vaccine (radiation attenuated sporozoites) trial in adolescents and children. The trial established a very good safety and tolerability profile for PFSPZ vaccine in younger age groups and well as better immune responses in younger children. This work was the basis for further studies in Equatorial Guinea, Kenya and other African countries.

Partners

Swiss Tropical and Public Health Institute
Sanaria Inc.

Funders

The government of Equitorial Guinea, Marathon Oil, Noble Energy and AMPCO
Medicines for Malaria Ventures (MMV)

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016